In Re: Zofran (Ondansetron)Products Liability Litigation

Track this case

Case overview

Case Number:

1:15-md-02657

Court:

Massachusetts

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Multi-district Litigation

Judge:

F. Dennis Saylor, IV

Firms

Companies

Glenmark Pharmaceuticals Ltd.

Sectors & Industries:

Healthcare
- Generic

March 01, 2024
GSK, Shook Hardy Can Recover Costs After Zofran MDL Win

GlaxoSmithKline and its attorneys from Shook Hardy & Bacon LLP can recover more than $450,000 in legal costs after beating a multidistrict suit claiming the company's anti-nausea drug Zofran caused birth defects, a federal judge has ruled.
March 16, 2023
Families In GSK MDL Rip Shook Hardy For 'Ironic' Costs Bid

Families that sued GlaxoSmithKline claiming its anti-nausea drug Zofran caused birth defects told a federal judge Wednesday that the company can't recoup roughly $578,000 in costs and called it "ironic" and "disheartening" because GSK's firm, Shook Hardy & Bacon LLP, had dropped a similar request in another multidistrict litigation.
June 25, 2021
Top Product Liability Cases Of 2021: Midyear Report

A U.S. Supreme Court ruling holding that Ford can be held liable for alleged defects in cars originally sold outside a plaintiff's home state and a ruling wiping out hundreds of cases alleging GlaxoSmithKline's anti-nausea drug Zofran causes birth defects are among Law360's top cases for the first six months of 2021.
June 18, 2021
GSK Gets Top Court Assist In MDL Victory 'Roadmap'

A sweeping order ending more than 400 cases alleging GlaxoSmithKline's anti-nausea medication Zofran causes birth defects provides a "roadmap" for fending off multidistrict litigation with the help of a landmark U.S. Supreme Court ruling, experts say.
June 01, 2021
Key Ruling Foils GSK Zofran MDL Ahead Of Bellwether

GlaxoSmithKline will not have to face more than 420 suits in multidistrict litigation alleging its anti-nausea medication Zofran causes birth defects, after a Massachusetts federal judge ruled Tuesday the claims are preempted because federal regulators declined to add a warning label for pregnant women.
April 21, 2021
Possible 'Showstopper' Ruling Looms In GSK Birth Defect Suit

A federal judge said during a Wednesday hearing that a ruling on whether claims that GlaxoSmithKline's anti-nausea medication Zofran triggers birth defects are preempted will be coming soon, a decision he's called a potential "showstopper" in the multidistrict suit.
March 24, 2021
GSK Says No Link Between Zofran, Defects Undermines MDL

Lawyers for GlaxoSmithKline argued Wednesday that more than 300 cases in a multidistrict product liability suit over its anti-nausea medication should be nixed since the plaintiffs' own expert determined there is no link between the drug and cardiac birth defects.
February 24, 2021
Zofran Birth Defect MDL Finally Heading For Trial In Fall

A Massachusetts federal judge running the first bellwether in multidistrict litigation over whether GlaxoSmithKline's anti-nausea medication Zofran causes birth defects said Wednesday that he's considering an October starting date after a lengthy postponement triggered by the coronavirus pandemic.
November 10, 2020
GSK Says FDA Rejected Zofran Label Change

GlaxoSmithKline on Monday told a Massachusetts federal judge overseeing multidistrict litigation over its anti-nausea medicine Zofran that the U.S. Food and Drug Administration has rejected a proposed label change that would have added birth defect warnings.
June 23, 2020
Pandemic May Push 1st Zofran MDL Bellwether To 2021

A Massachusetts federal judge told lawyers representing GlaxoSmithKline and plaintiffs who claim its anti-nausea medicine Zofran caused birth defects that he's open to creative ways to hold a complex jury trial with social distancing, but he may have no choice but to wait until 2021.

← Previous
1
2
3
4
5
Next →